<DOC>
	<DOCNO>NCT00862589</DOCNO>
	<brief_summary>The incretin hormone glucagon-like peptide-1 ( GLP-1 ) know insulinotrophic glucagonostatic property . However , inpatient type 2 diabetes mellitus ( T2DM ) show , beta cell sensitivity towards GLP-1 decrease , compare healthy control . Further , patient decrease GLP-1 response meal . The aim study elucidate diabetic hyperglucagonemia , see patient fast postprandial condition , course decreased sensitivity GLP-1 diabetic alpha cell . Ten T2DM patient ten match healthy control subject examine two separate day . Day 1 : increase GLP-1 infusion Day 2 : saline . During day plasma glucose ( PG ) clamp fast level ( FPG ) . Patients T2DM submit til Day 3 , PG normalize over-night adjustable insulin infusion , follow day GLP-1 infusion Day 1 repeat . The hypothesis patient decrease alpha cell sensitivity GLP-1 case beta cell sensitivity . This decreased sensitivity , investigator speculate , contributes defect suppression og glucagon thereby increase PG level see T2DM . Further investigator elucidate sensitivity increase normalizing diabetic PG normal FPG level .</brief_summary>
	<brief_title>Glucagon-Like Peptide-1 ( GLP-1 ) Suppression Alpha Cell Secretion Type 2 Diabetes Mellitus ( T2DM )</brief_title>
	<detailed_description />
	<mesh_term>Hyperglycemia</mesh_term>
	<mesh_term>Glucose Intolerance</mesh_term>
	<mesh_term>Glucagon</mesh_term>
	<mesh_term>Glucagon-Like Peptide 1</mesh_term>
	<criteria>T2DM accord WHO criteria Written consent Age &gt; 18 year Kidney hepatic disease Treatment insulin glitazone</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2009</verification_date>
	<keyword>glucagon</keyword>
	<keyword>GLP-1</keyword>
	<keyword>hyperglycemia</keyword>
</DOC>